Grant Award Details
- To develop an allogeneic, iPSC-derived CAR NK cell therapy targeting SARS-CoV-2
Grant Application Details
- Chimeric Antigen Receptor Targeting Spike Glycoprotein of SARS-cov2
We expect to generate iPSC derived NK cells expressing a CAR against SARS-cov2 that could be used as an off-the-shelf therapy for COVID-19
The proposed studies will provide a novel therapeutic approach to boost the cellular immunity against SARS-cov2, especially for high risk populations.
Major Proposed Activities
- Construction of SARS-cov2 CAR constructs
- Generation of iPSC-derived NK cells expressing CARs
- Differentiation of iPSC-CAR cells into hematopoietic progenitors
- Derivation of human NK-CAR cells
- In vitro studies of iPSC derived NK-CAR cells
- In vivo studies of iPSC-derived NK CAR cells
The SARS-cov2 is the etiological agent of COVID-19, a global pandemic that has caused more than 4200 deaths in California. The proposed studies will provide a novel therapeutics to improve the immune response to COVID-19.